diagnostic confi rmation normally accomplished using fast atom bombardment (FAB)-MS measurement of elevated urinary bile alcohol glucuronides (18) (19) (20) , which are more specifi c markers for CTX. Neither test would be useful as a biochemical test in newborn screening laboratories, where electrospray ionization-tandem MS (ESI-MS/MS) analysis of DBS is routinely performed.
A focus of our research has been to develop highthroughput, amenable ESI-MS/MS-based blood tests with utility to screen DBS for CTX ( 21, 22 ) . We previously utilized keto-moiety derivatization with Girard's P reagent (1-(carboxymethyl) pyridinium chloride hydrazide) ( 23, 24 ) to enable sensitive isotope dilution LC-ESI-MS/MS quantifi cation of plasma ketosterol BA precursors that accumulate in CTX (25) (26) (27) . Although the method lower limit of quantifi cation (LLOQ) that we reported (50-100 ng/ml) was close to the maximum circulating concentration of 7 ␣ -hydroxy-4-cholesten-3-one (7 ␣ C4) in healthy individuals (28) (29) (30) (31) , we demonstrated 7 ␣ C4 possessed improved diagnostic utility over 5 ␣ -cholestanol as a marker of CTX ( 21 ) . Recently keto derivatization with quaternary amonoxy (QAO) O -(3-trimethylammonium-propyl) hydroxylamine reagent to form a cationic oxime derivative enabled highly sensitive LC-ESI-MS/MS quantifi cation of testosterone ( 32 ) . We describe here development and application of this methodology utilizing QAO derivatization for LC-ESI-MS/MS quantifi cation of ketosterol BA precursors in very small volumes of plasma (4 l) or 3.2 mm DBS punches. The availability of isotopically enriched CTX; for example, in an isolated Israeli Druze community, a carrier frequency of 1:11 for the deleterious c.355delC mutation was reported ( 7, 8 ) . Despite these observations, only around three hundred cases of CTX have been described worldwide ( 9 ) , although large series of patients have been described by physicians with experience in recognizing the disorder in Italy ( 9, 10 ) , the Netherlands ( 3, 4 ) , Japan ( 11 ) , Spain ( 5 ) , the United States, and Israel ( 12 ) . CTX is likely not well recognized and under-or misdiagnosed.
An effective therapy for CTX is available in the form of oral CDCA, the main BA defi cient in CTX. CDCA treatment has been shown to normalize the biochemical phenotype and halt progression of disease ( 10, 12 ) . There are reports indicating treatment prevents the onset of disease complications in presymptomatic children ( 13, 14 ) . Cholic acid treatment has been reported to be a less hepatotoxic alternative to CDCA in infants ( 13 ) . Although treatment at every stage of disease is recommended ( 15 ) , in many cases, treatment of patients with advanced neurological disease does not reverse the neurological impairment ( 10 ) . Therefore, it is essential to diagnose and treat CTX as early as possible.
Although CTX fulfi lls the majority of criteria required for a disorder to be screened for in newborns, there is no suitable test to screen newborn dried bloodspots (DBS) for CTX. Blood testing for CTX is routinely performed using gas chromatography-mass spectrometry (GC-MS) measurement of elevated 5 ␣ -cholestanol ( 16, 17 ) , with Pathways to primary BA. The major adult pathway is the neutral pathway initiated by CYP7A1-mediated 7 ␣ -hydroxylation of cholesterol. There is a minor pathway to CDCA termed the acidic pathway initiated by CYP27A1-mediated 27-hydroxylation of cholesterol followed by oxysterol 7 ␣ -hydroxylation. Synthesis of CDCA through both pathways is blocked in CTX with accumulation of ketosterol BA precursors, such as 7 ␣ C4 (from which most 5 ␣ -cholestanol is derived). Highlighted in dark gray are the disease markers routinely used to test for CTX; 5 ␣ -cholestanol in blood ( 16, 17 ) , and bile alcohols (primarily pentol) in urine (18) (19) (20) , and in light gray, ketosterol BA precursors, quantifi cation of which we describe here provides an improved blood test for CTX. 
Preparation of calibrators and samples for LC-MS/MS measurement of ketosterols
For the LC-ESI-MS/MS method, calibrators were generated using dilutions of authentic standard in methanol. The dilutions were spiked into DCS plasma or pooled whole blood from unaffected individuals (which was used to create DBS by pipetting 100 l aliquots onto fi lter paper and air drying for 1 h). For calibrators or samples, 300 pg 7 ␣ C4-d 7 internal standard in 10 l methanol was added to either 4 l plasma or 3.2 mm DBS punches followed by 80 l QAO reagent solution (210 g in methanol plus 5% acetic acid, v/v). The mixture was vortexed and kept at room temperature for 2 h, at which point QAO derivatization was complete (<2% underivatized ketosterol could be detected by LC-ESI-MS/MS). Ten microliters of water and 300 pg of previously prepared QAO-d 3 7 ␣ C4 and QAO-d 3 7 ␣ 12 ␣ C4 internal standards in 10 l methanol were added. Prior to LC-MS/MS analysis, any precipitate was removed using Ultrafree 0.45 m centrifugal fi lters from Millipore (Billerica, MA). 3 7 ␣ C4 and QAO-d 3 7 ␣ 12 ␣ C4 internal standards 7 ␣ C4 and 7 ␣ 12 ␣ C4 were tagged with isotopically enriched QAO reagent to prepare internal standards by derivatization of 30 ng of 7 ␣ C4 and 7 ␣ 12 ␣ C4 using 942 l QAO-d 3 reagent (2.8 mg/ml) in methanol at 5% acetic acid. This reaction was kept at room temperature for 18 h; the underivatized ketosterols were monitored to ensure greater than 98% derivatization. This mixture was frozen without purifi cation, and aliquots of QAO-d 3tagged ketosterol internal standards were directly added to plasma and DBS samples after 2 h of derivatization with QAO-d 0 reagent.
Preparation of QAO-d

LC-ESI-MS/MS optimization
LC-ESI-MS/MS experiments were performed, and the method was validated using a QTRAP® 5500 triple-quadrupole hybrid mass spectrometer with linear ion trap functionality (AB SCIEX, Framingham, MA), equipped with a TurboIonSpray® ESI source. The ionization interface was operated in the positive mode using the following settings: TEM 500°C, IS 5.0 kV; and CUR, GS2, and GS1 nitrogen gas fl ow rates, 40, 40, and 30 psi, respectively. For QAO derivatives and underivatized ketosterols, the multiple reaction monitoring (MRM) transitions monitored for quantifi cation were as follows (all at EP 10 V with dwell times of 40 ms): for QAO 7 ␣ C4, m/z 515.7 → 152.3 quantifi er (CE 65eV, DP 71eV, and CXP 4eV) and m/z 515.7 → 438.6 qualifi er (CE 65eV, DP 76eV and CXP 6eV); for QAO 7 ␣ 12 ␣ C4, m/z 531.7 → 152.1 qualifi er (CE 65eV, DP 71eV, and CXP 4eV), and m/z 531.7 → 454.5 qualifi er (CE 65eV, DP 76eV, and CXP 6eV); for QAO 7 ␣ C4-d 7 , m/z 522.7 → 152.2 (CE 70eV, DP 71eV, and CXP 8eV); for QAO-d 3 7 ␣ C4, m/z 518.7 → 152.3 (with CE 70eV, DP 85eV, and CXP 8eV); and for QAO-d 3 7 ␣ 12 ␣ C4, m/z 534.7 → 152.1 (CE 65eV, DP 71eV, and CXP 4eV). For underivatized 7 ␣ C4 (monitored to ensure complete derivatization), the MRM transition was m/z 401.6 → 97.2 (CE 50eV, DP 71eV, and CXP 8eV). The QTRAP® 5500 was coupled to a Shimadzu UPLC system (Columbia, MD) composed of a SIL-20ACXR auto-sampler and two LC-20ADXR LC pumps. QAO derivatives of 7 ␣ C4 and 7 ␣ 12 ␣ C4 were resolved using a 50 × 2.1(i.d.) mm, 5.0 m Luna C 8 -HPLC column with guard (Phenomenex; Torrance, CA). The gradient mobile phase was delivered at a fl ow rate of 0.8 ml/min. The mobile phase consisted of two solvents: A, water:acetonitrile (98:2 v/v) at 0.1% formic acid, and B, water:acetonitrile (10:90 v/v) at 0.1% formic acid. Solvent B was increased from 10% to 60% over 2 min, kept at 60% for 1 min, then increased from 60% to 100% over 0.2 min. The column was washed at 100% B for 1.8 min, decreased to 10% derivatization reagent allowed ready tagging of different ketosterols to generate stable isotope-labeled derivative internal standards for isotope dilution quantifi cation. Free (nonhydrolyzed) ketosterol BA precursors in plasma or DBS, including newborn DBS, were quantifi ed, and their utility as markers for CTX was compared with hydrolyzed 5 ␣ -cholestanol.
MATERIALS AND METHODS
Human subject research considerations
Whole blood and plasma was purchased commercially or was obtained from participants enrolled in studies at Oregon Health & Science University (OHSU) under Institutional Review Board (IRB)-approved protocols. Informed consent was obtained from all study participants. De-identifi ed clinical samples submitted to the OHSU Lipid Laboratory for diagnostic confi rmation of CTX using GC-MS measurement of elevated plasma 5 ␣ -cholestanol were used with IRB approval. For CTX-positive samples, diagnostic confi rmation was by molecular genetic testing performed by the Molecular Diagnostics Laboratory of J. Chiang at OHSU. Deidentifi ed DBS from newborns later diagnosed with CTX from the Ontario and California newborn screening programs, as well as anonymized residual newborn DBS from the Oregon State Public Health Laboratory, were used with IRB approval.
Chemicals and reagents
7 ␣ -Hydroxy-4-cholesten-3-one (7 ␣ C4), 7 ␣ -hydroxy-4-cholesten-3-one-d 7 (7 ␣ C4-d 7 ), and 7 ␣ , 12 ␣ -hydroxy-4-cholesten-3-one (7 ␣ 12 ␣ C4) were from Toronto Research Chemicals (Toronto, Ontario). 5 ␣ -cholestanol was from Steraloids (Newport, RI) and epicoprostanol from Sigma-Aldrich (St. Louis, MO). BSTFA reagent was from Thermo Scientifi c (Bellefonte, PA). Human plasma, double charcoal-stripped (DCS) plasma, and whole blood were from Golden West Bio (Temecula, CA). Methanol and water (GC-MS grade) were from Burdick and Jackson (Muskegon, MI). Formic acid (90%) was J.T. Baker brand, and glacial acetic acid (99.99%) was from Aldrich. QAO reagent (O-(3-trimethylammoniumpropyl) hydroxylamine) bromide is commercially available as Amplifex TM Keto reagent from http:// www.sciex.com. The QAO-d 3 reagent was provided by AB SCIEX. Protein Saver 903 and DMPK A and DMPK B fi lter papers were obtained from Whatman (Miami, FL).
Preparation of calibrators and samples for GC-MS measurement of 5 ␣ -cholestanol
The GC-MS analysis method for measurement of elevated plasma 5 ␣ -cholestanol was modifi ed from a published method ( 33 ) . In brief, internal standard (epicoprostanol) was added to plasma or DBS samples or to calibrants generated using 5 ␣cholestanol. Sterols were saponifi ed by the addition of ethanol/ KOH, incubated at 37°C for 1 h, and then the aqueous phase was extracted twice with hexane. The combined hexane extracts were evaporated and derivatized with BSTFA at 80°C for 30 min. Concentrations of the trimethylsilyl ether derivatives of 5 ␣ -cholestanol were measured using GC (pulsed/splitless injection with an Agilent GC 6890N) performed with a ZB1701 column (30m, 0.25 mm ID, 0.25 µm fi lm thickness; Phenomenex, Torrance, CA) coupled to a mass spectrometer (MS 5975; Santa Clara, CA). Mass spectra were collected in selected ion mode (with m/z 355 and 370 ions monitored for epicoprostanol, and m/z 306 and 305 ions monitored for 5 ␣ -cholestanol). 
RESULTS
LC-ESI-MS/MS method
The QAO reagent introduces a trimethyl ammoniumcharged moiety that couples to the ketosterol ketone functionality via oxime bond formation ( 32 ) 
Comparison of quantifi cation using commercially available ketosterol-d x analog as internal standard versus quantifi cation using QAO-d x -tagged ketosterol as internal standard
DCS plasma calibration curves for QAO-tagged 7 ␣ C4 analyte with QAO-tagged 7 ␣ C4-d 7 internal standard demonstrated acceptable linearity and a mean correlation coefficient r 2 = 0.992 across the range 10-250 ng/ml (n = 6). From the concentrations calculated for 10, 20, 50, and 250 ng/ml QCs, the LLOQ for 7 ␣ C4 in plasma was determined to be B over 0.1 min, and reequilibrated at 10% B for 1.4 min. The column temperature was kept at 35°C using a Shimadzu CTO-20AC column oven. The sample injection volume was 10 l.
Data analysis
To calculate analyte concentrations, calibration curves were generated by performing a least-squares linear regression for peak area ratios (QAO-d 0 7 ␣ C4 analyte/QAO-d 0 7 ␣ C4-d 7 internal standard or QAO-d 3 7 ␣ C4 internal standard and QAO-d 0 7 ␣ 12 ␣ C4 analyte/QAO-d 3 7 ␣ 12 ␣ C4 internal standard) plotted against specifi ed calibrant concentration in plasma (ng/ml). The analyte and internal standard peaks were integrated as previously described ( 32 ) .
Method performance
The LLOQ was determined as the lowest spiked concentration in the matrix for which the signal-to-noise (S/N) ratio was greater than 5 and the reproducibility of calculated concentrations was less than or equal to 20% relative standard deviation (RSD). Within-day reproducibility was determined using calculated concentrations for quality control (QC) samples generated by spiking 7 ␣ C4 and 7 ␣ 12 ␣ C4 into DCS plasma or whole blood spotted onto fi lter paper. Between-day reproducibility was determined using calculated concentrations for QCs analyzed on different days. Potential method interference was carefully evaluated by examination of the peak shape, peak shoulder, and peak area ratio of two MRM transitions (quantifi er and qualifi er) acquired for each analyte ( 34 ) . The selectivity of the method was also evaluated by analysis of possible method interference by, for example, endogenous regioisomers of 7 ␣ C4 and 7 ␣ 12 ␣ C4, such as 7-ketocholesterol (Steraloids) and 3 ␤ ,27-dihydroxy-5-cholesten-7-one (Avanti, Alabaster, AL). Carryover from the auto-sampler was determined by assessing carryover from a 2,500 ng/ml sample. The extraction effi ciency of 7 ␣ 12 ␣ C4 from fi lter paper was determined by comparing the QAO 7 ␣ 12 ␣ C4 peak area for ketosterol calibrators spotted onto fi lter paper against calibrators not spotted onto fi lter paper. The matrix effect was determined in two ways: by comparing the QAO ketosterol peak area for matrixbased calibrators against nonmatrix calibrators and by using the post-column infusion method ( 35 ) . The stability of QAOtagged ketosterols in matrix stored at Ϫ 20°C or Ϫ 80°C for 1 week and at room temperature or at 4°C for 8 h was assessed. transitions was obtained with a RSD of 14% (for n = 120 samples and calibrants у 20 ng/ml, with <5% not within ± 2 SD), and for 7 ␣ 12 ␣ C4 in plasma, a mean peak area ratio was obtained with a RSD of 10% (for n = 120 samples and calibrants у 20 ng/ml, with <1% not within ± 2 SD). Method interference precluded measurement of 7 ␣ C4 in whole-blood spotted onto fi lter paper. An interfering peak was extracted from fi lter paper (detected with both qualifi er and quantifi er MRM transitions) that coeluted with 7 ␣ C4 even under shallower gradient or isocratic HPLC elution. The interfering peak was extracted from Protein Saver 903, as well as Whatman DMPK A and DMPK B fi lter paper (data not shown). For measurement of 7 ␣ 12 ␣ C4 in DBS, a mean peak area ratio for quantifi er and qualifi er MRM transitions was obtained with a RSD of 7.5% (for n = 70 samples and calibrants у 20 ng/ml; with <4% not within ± 2 SD). The selectivity of the method was also evaluated by analysis of endogenous regioisomers of 7 ␣ C4 and 7 ␣ 12 ␣ C4 reported to be present: 7-ketocholesterol and 3 ␤ ,27-dihydroxy-5-cholesten-7-one. These ketosterols (at 100 ng/ml) were derivatized and analyzed using the LC-ESI-MS/MS method to ensure they did not coelute with QAO-tagged 7 ␣ C4 or 7 ␣ 12 ␣ C4. Between injection carryover for 7 ␣ C4 and 7 ␣ 12 ␣ C4 from the auto-sampler was assessed and determined to be <0.1%.
Extraction effi ciency. The extraction effi ciency of 7 ␣ 12 ␣ C4 from fi lter paper was determined by comparing the QAOtagged 7 ␣ 12 ␣ C4 peak area for calibrators spotted onto fi lter paper and derivatized against calibrators not spotted onto fi lter paper. The mean extraction effi ciency of 7 ␣ 12 ␣ C4 from fi lter paper across the range 20-250 ng/ml was 92%.
Matrix effect. The matrix effect was determined by comparing the QAO-tagged ketosterol peak area for matrixbased against nonmatrix calibrators and by the post-column infusion method ( 35 ) where a solution of QAO-tagged ketosterol (0.1 ng/ml in methanol) was continuously infused 20 ng/ml and the upper limit of quantifi cation 250 ng/ml (accuracy and precision data not shown).
The availability of isotopically enriched derivatization reagent allowed the ready preparation of QAO-d 3 -tagged ketosterols as internal standards for isotope dilution quantifi cation. To validate use of QAO-d 3 -tagged ketosterol as an internal standard, DCS plasma calibration curves were generated for QAO-d 0 -tagged 7 ␣ C4 with QAO-d 3 -tagged 7 ␣ C4 internal standard (acceptable linearity and characteristic correlation coeffi cients r 2 > 0.990, data not shown). The accuracy and precision data for 7 ␣ C4 concentrations calculated using QAO-d 3 -tagged 7 ␣ C4 internal standard ( Table 1 ) was comparable to the data using QAO-tagged 7 ␣ C4-d 7 internal standard. A comparison of calculated 7 ␣ C4 concentrations was performed for n = 200 plasma samples, QCs, and calibrators using either QAO-d 0 -tagged 7 ␣ C4-d 7 or QAO-d 3 -tagged 7 ␣ C4-d 0 as internal standard (options I and 2, respectively, in Fig. 2A ) . The calculated 7 ␣ C4 concentrations demonstrated acceptable correlation (r 2 = 0.984; Fig. 2B ).
After validating the use of QAO-d 3 -tagged ketosterol as internal standard, we prepared QAO-d 3 -tagged 7 ␣ 12 ␣ C4 internal standard. DCS plasma calibration curves for QAO-tagged 7 ␣ 12 ␣ C4 with QAO-d 3 -tagged 7 ␣ 12 ␣ C4 internal standard demonstrated acceptable linearity (mean correlation coefficient across the plasma range 20-250 ng/ml of r 2 = 0.997; n = 6). The LLOQ determined for 7 ␣ 12 ␣ C4 in plasma was 20 ng/ml (for accuracy and precision data, see Table 1 ).
A DBS calibration curve for 7 ␣ C4 could not be generated as method interference precluded measurement of 7 ␣ C4 in DBS. DBS calibration curves for QAO-tagged 7 ␣ 12 ␣ C4 with QAO-d 3 -tagged 7 ␣ 12 ␣ C4 internal standard demonstrated acceptable linearity and a mean correlation coeffi cient of r 2 = 0.997 across the range 50-250 ng/ml (n = 5; for accuracy and precision data, see Table 1 ).
LC-ESI-MS/MS method performance studies
Selectivity. For measurement of 7 ␣ C4 in plasma, a mean peak area ratio for quantifi er and qualifi er MRM overlap between the concentrations found in CTX-affected and unaffected adults ( Table 2 ). The concentration of 7 ␣ 12 ␣ C4 in adult DBS was similar to concentrations found in plasma, with highly disparate concentrations observed between unaffected and CTX-affected adult samples (see Table 2 and Fig. 4A ). Despite calculated 7 ␣ 12 ␣ C4 concentrations outside the measurable range, the mean concentration of 7 ␣ 12 ␣ C4 in CTX-affected adult DBS was 1385-fold the mean concentration in unaffected adult DBS, with no overlap between the concentrations in CTX-affected and unaffected adult samples ( Table 2 ) . In contrast, the mean DBS concentration of 5 ␣ -cholestanol measured by GC-MS in CTX-affected adults was only 7.6fold the mean concentration in unaffected adults.
Through signifi cant effort and collaboration, we were able to obtain two newborn DBS samples from individuals diagnosed with CTX later in life (between 5 and 15 years old). Although the DBS had been stored at room temperature for between 15 and 25 years, we were able to measure elevated 7 ␣ 12 ␣ C4 in both samples (120-214 ng/ml). While the CTX (asymptomatic) newborn DBS concentrations of 7 ␣ 12 ␣ C4 were around 10-fold lower than the mean CTX (symptomatic) adult DBS concentration, they were 10-fold greater than the mean unaffected newborn DBS 7 ␣ 12 ␣ C4 concentration ( Table 2 and Fig. 4B ) , with no overlap between concentrations in affected and unaffected DBS. In contrast, the CTX newborn DBS concentrations of 5 ␣ -cholestanol were only around 2-fold the mean 5 ␣ -cholestanol concentration in unaffected newborn DBS, with some overlap between the 5 ␣ -cholestanol concentrations in unaffected newborns and affected adult DBS.
DISCUSSION
Due to the poor ionization effi ciency of neutral sterols, derivatization to incorporate an ionizable moiety or into the ESI source while a QAO-derivatized blank DCS plasma or DBS sample was analyzed. Signal suppression was estimated by observing the loss in signal for infused QAOtagged ketosterols at their respective elution times. The mean signal suppression from four experiments due to matrix interference from plasma was calculated to be 29% (21% RSD) for QAO-tagged 7 ␣ C4 and 36% (21% RSD) for QAO-tagged 7 ␣ 12 ␣ C4 across the range 20-250 ng/ml. The signal suppression calculated due to matrix interference from DBS was 21% (15% RSD) for QAO-tagged 7 ␣ 12 ␣ C4 across the range 20-250 ng/ml. Stability studies. Ketosterols spiked into DCS plasma (7 ␣ C4 and 7 ␣ 12 ␣ C4) and DBS (7 ␣ 12 ␣ C4) over the calibration curve range were stable when stored at Ϫ 20°C and Ϫ 80°C for 1 week at room temperature and at 4°C for 8 h (a comparison of absolute peak area, as well as peak area ratio of analyte to internal standard demonstrated each condition differed from a mean value at time zero by less than 10%). It was previously reported that 7 ␣ C4 was stable in plasma stored at Ϫ 20°C for up to 10 months ( 30 ) . QAO derivatives in aqueous quenched derivatization solvent were stable kept in the auto-sampler for 24 h at room temperature (exhibiting a loss in absolute peak area but differing from a mean value at time zero by less than 5%). Methanol dilutions of 7 ␣ C4 and 7 ␣ 12 ␣ C4 were stable at Ϫ 80°C for at least 1 year ( 21 ) .
Quantifi cation of endogenous ketosterols as a blood test for CTX
RICs for detection of QAO-tagged ketosterols illustrate detection of 7 ␣ C4 and 7 ␣ 12 ␣ C4, respectively ( Fig. 3A , B ), in plasma from unaffected and CTX-affected adults. CTX adult plasma samples with concentrations greater than 250 ng/ml were diluted 25-fold and reanalyzed. The mean plasma concentrations of 7 ␣ C4, 7 ␣ 12 ␣ C4, and 5 ␣ -cholestanol measured in CTX-affected adults were, respectively, 183-, 3862-, and 24fold the mean concentrations in unaffected adults, with no The acidic BA pathway initiated by cholesterol 27hydroxylation (lower pathway in Fig. 1 ) has been proposed to be the major BA synthesis pathway in neonates, as deficiency in the oxysterol 7 ␣ -hydroxylase enzyme (CYP7B1) can cause severe liver disease in infancy (36) (37) (38) . Our data and the recent observation that CYP7B1 mutations also cause a form of hereditary spastic paraplegia with disease onset outside of the newborn period ( 39 ) suggest that when the acidic pathway is blocked, neonates are able to synthesize BA via the neutral pathway. This hypothesis is also supported by clinical observations in CTX. Generally affected newborns survive the newborn period and serious complications of the disorder present later in life. Some cholic acid is likely formed in CTX newborns via diversion of the neutral BA pathway through bile alcohols (in CTX adults, cholic acid can be synthesized through bile alcohols formed from 5 ␤ -cholestane-3 ␣ ,7 ␣ ,12 ␣ -triol by microsomal 25-followed by 24-or 23-hydroxylation; see Fig. 1 ). Elevated bile alcohol intermediate 5 ␤ -cholestane-3 ␣ ,7 ␣ ,12 ␣ ,25-tetrol was previously detected in serum from a four-month-old CTX patient ( 1 ) . permanent charge has been utilized to improve sensitivity for ESI or atmospheric pressure chemical ionization-MS/MS sterol detection. We previously explored Girard P derivatization of ketosterols, such as 7 ␣ C4, to form hydrazones ( 21 ) . This methodology was limited by an LLOQ of 50-100 ng/ml (close to the maximum circulating concentration of 7 ␣ C4) ( 29 ) . The keto moiety of sterols or steroids has also been derivatized with aminooxy reagents to form oxime derivatives, for example, using hydroxylamine or QAO reagent ( 32 ) . A higher equilibrium constant for oxime over hydrazone formation results in improved room temperature stability for oxime derivatives. In addition, fragmentation of QAO derivatives can produce unique fragments that result in lower background noise ( 32 ) . We report here that LC-ESI-MS/MS methodology utilizing QAO derivatization, with simple and rapid sample preparation amenable to automation and analysis times of 4-6 min using conventional LC instrumentation and buffers, enabled sensitive isotope dilution quantifi cation of ketosterol BA precursors and allowed characterization of their utility as markers for CTX compared with 5 ␣ -cholestanol. There are concerns regarding the specifi city of 5 ␣cholestanol as a marker for CTX as it can be elevated in other disorders (for example, sitosterolemia and liver disease) ( 40 ) . Although 7 ␣ C4 can also be elevated in BA malabsorption and ileal resection ( 41 ) , we previously reported that 7 ␣ C4 demonstrated improved utility over 5 ␣ -cholestanol as a circulating marker for CTX ( 21 ) . Studies are under way in our laboratory to determine whether 7 ␣ 12 ␣ C4 is a more specifi c marker for CTX than 7 ␣ C4. The data we present here, that the mean circulating concentration of 7 ␣ 12 ␣ C4 in CTX-affected individuals is 3,862-fold the mean control concentration, suggests 7 ␣ 12 ␣ C4 may be a more unique marker for CTX. Bjorkhem and colleagues reported that in CTX hepatic tissue elevation of 7 ␣ 12 ␣ C4 over control values was greater than elevation of 7 ␣ C4, as well as downstream 7 ␣ 12 ␣ C4 derivatives formed in the pathway to bile alcohols, such as 7 ␣ ,12 ␣ -dihydroxy-5 ␤ -cholestan-3-one and 5 ␤ -cholestane-3 ␣ ,7 ␣ ,12 ␣ -triol ( 25 ) .
In summary, we describe here LC-ESI-MS/MS methodology that utilizes keto-moiety derivatization with QAO reagent to enable highly sensitive isotope dilution quantifi cation of 7 ␣ C4 and 7 ␣ 12 ␣ C4 in plasma or DBS from CTX-affected adults and newborns. Quantifi cation of 7 ␣ 12 ␣ C4 provides improved discrimination between CTX and unaffected samples compared with 5 ␣ -cholestanol, such that it serves as an improved blood test for CTX. Although accumulation of ketosterol BA precursors has been previously reported in affected adults and adolescents ( 1, 25, 26 ) , we demonstrate for the fi rst time that elevated 7 ␣ 12 ␣ C4 can be measured in DBS obtained from affected newborns. With the limitation that we were able to retrieve and analyze only two DBS from individuals with adolescent onset disease, there appears to be no overlap between concentrations of 7 ␣ 12 ␣ C4 in affected and unaffected samples, thus potentially enabling the screening of newborn DBS for CTX.
